内部收购后雅塔拉股价上涨

2025-07-23 03:02

Shares of Atara Biotherapeutics (NASDAQ:ATRA) spiked for the second straight session on Tuesday following an insider purchase of more than 19K company shares by Panacea Innovation Ltd., an investor with over 10% ownership in the California-based biotech.
According to a regulatory filing on Monday, the British venture capital firm purchased a little over 19.3K ATRA shares on July 17 for nearly $9.64 each in a transaction worth ~$186.4K.
Panacea Innovation recorded a holding of 1.35M ATRA shares before the purchase, implying ~23% of outstanding shares of the company’s common stock as of May 9, 2025.
The transaction comes after Atara (NASDAQ:ATRA) shares climbed more than 25% over the past 12 months despite the FDA’s rejection of its immunotherapy candidate, Ebvallo, and a clinical hold that impacted several of its development programs early this year.

More on Atara Biotherapeutics